All News from Accelerate Diagnostics

All News

Accelerate Diagnostics and BioCheck join the fight against COVID-19

Apr 15, 2020 — On April 15, 2020, Accelerate Diagnostics and BioCheck announced a commercial supply and collaboration agreement by which Accelerate will distribute the BioCheck MS-FAST system and BioCheck SARS-CoV-2 tests in North America, Europe, and the Middle East. The BioCheck MS-FAST system, a fully automated chemiluminescence immunoassay analyzer, and the BioCheck SARS-CoV-2 chemiluminescence-based tests are capable of […]

Continue reading ›

Clinicians at Moffitt Cancer Center make a difference for patients by optimizing antibiotic therapy earlier

Mar 06, 2020 — Mary Meyer, a transplant patient at Moffitt Cancer Center recently experienced first-hand how beneficial same-day antimicrobial susceptibility results can be. Ms. Meyer was treated in the Moffitt Urgent Care center for an unknown infection. Doctors there tested her blood using the Accelerate Pheno system, a new diagnostic system that can identify bacteria and provide antimicrobial […]

Continue reading ›

Accelerate Diagnostics Reports Fourth Quarter 2019 Financial Results

Feb 27, 2020 — Accelerate Diagnostics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2019. “Our contracted instrument trajectory continued over the course of 2019 as we doubled our global contracted instrument base by signing 304 instruments, including 137 units during the fourth quarter. Our full-year revenue was short of expectations as multi-site […]

Continue reading ›

HealthLeaders: Allegheny Health Network benefits from new rapid test

Feb 10, 2020 — From HealthLeaders: For the past eight months, the team at Allegheny Health Network has been using the Accelerate Pheno test system to analyze bloodstream infections and determine the best antibiotic therapy for sepsis patients. Sepsis is the body’s extreme reaction to an infection, which can result in life-threatening symptoms such as multiple organ failure. Annually, […]

Continue reading ›

Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results

Jan 13, 2020 — TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and Full-Year Financial Highlights Commercially contracted instruments were 137 in the fourth quarter and 304 […]

Continue reading ›

Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]

Continue reading ›

Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019.   “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]

Continue reading ›

Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit

Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]

Continue reading ›

University of Iowa Hospitals & Clinics announces adoption of Accelerate Pheno

Jan 16, 2019 — University of Iowa Hospitals & Clinics recently shared their adoption of the Accelerate Pheno™ system as a “new technology that helps diagnose and treat sepsis—a potentially life-threatening infection in the blood—faster than ever before.” Get the full story from UI Health Care Quick story excerpt: “Every hour counts,” explains Bradley Ford, MD, PhD, medical director […]

Continue reading ›

Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results

Jan 06, 2019 — Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth quarter, and […]

Continue reading ›